Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
80.38
+0.91 (1.15%)
Dec 5, 2025, 4:00 PM EST - Market closed
Monopar Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Monopar Therapeutics stock have an average target of 97.83, with a low estimate of 40 and a high estimate of 125. The average target predicts an increase of 21.71% from the current stock price of 80.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 7 | 6 | 5 | 5 |
| Buy | 3 | 3 | 4 | 5 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy → Buy Downgrades $142 → $123 | Strong Buy → Buy | Downgrades | $142 → $123 | +53.02% | Nov 14, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $100 | Strong Buy | Maintains | $100 | +24.41% | Nov 13, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $115 | Buy | Initiates | $115 | +43.07% | Nov 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $85 → $100 | Strong Buy | Maintains | $85 → $100 | +24.41% | Nov 9, 2025 |
| Barclays | Barclays | Buy Initiates $125 | Buy | Initiates | $125 | +55.51% | Oct 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.70
from -4.11
EPS Next Year
-3.75
from -1.70
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.52 | -1.16 | ||||
| Avg | -1.70 | -3.75 | ||||
| Low | -1.87 | -6.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.